In through the out door: Serology for atrophic gastritis

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 8, 2003, Pages 877-879

  Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atrophic gastritis; Gastritis; Helicobacter pylori; Pepsinogen; Serology

Indexed keywords

ANTIBODY DETECTION; ATROPHIC GASTRITIS; BACTERIAL INFECTION; GASTRITIS; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SEROLOGY; STOMACH CANCER; STOMACH MUCOSA; WORLD HEALTH ORGANIZATION;

EID: 0042816467     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200308000-00007     Document Type: Review

References (15)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349:1269-1276.
2. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; ii:58-59.
3. Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G, Nelis GF, et al. Long term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345:1525-1526,
4. Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1965; 35:173-177.
5. Kuipers EJ. Review article: relationship between Helicobacter pylori, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther 1998; 12 (suppl 1):25-36.
6. Passaro DJ, Hurwitz A, Triadafilopoulos G, Parsonnet J. A modification of the quininium resin test for assessing gastric acidity. Aliment Pharmacol Ther 2002; 16:875-880.
7. Kuipers EJ, Peña AS, Crusius JBA, Defize J, van der Stoop P, Meuwissen SGM, Pals G. Absence of pepsinogen A-3 gene expression in the gastric mucosa of patients with gastric cancer. J Clin Pathol 1995; 48:376-379.
8. Westerveld BD, Pals G, Lamers CBHW, Defize J, Pronk JC, Frants RR, et al. Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 1987; 59:952-958.
9. Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Sanchez Figueroa L, Halperin D, Parsonnet J. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomark Prev 2001; 10:107-112.
10. Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yoshida H, Kawa T, et al. Weak response of Helicobacter pylori antibody is high risk for gastric cancer: a cross-sectional study of 10 234 endoscoped Japanese. Scand J Gastroenterol 2002; 37:148-153.
11. Oksanen A, Sipponen P, Karttunen R, Miettinen A, Veijola L, Sarna S, Rautelin H. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut 2000; 46:460-463.
12. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15:885-891.
13. Chun Yu Wong B, Lam SK, Wong W-M, Zheng T, Chen J, Chen B, et al. Eradicating Helicobacter pylori infection in general population prevents gastric cancer: a 7-year prospective randomized placebo-controlled study. Gastroenterology 2002; 122 (suppl 1):A588.
14. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348:150-154.
15. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 61: Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC; 1994.